Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: The fat-to-muscle mass ratio (FMR) is an innovative metric that integrates fat and muscle constituents. The aim of this study was to examine the efficacy of FMR in predicting non-alcoholic fatty liver disease (NAFLD) in individuals with T2DM.

Methods: This cross-sectional study enrolled 307 hospitalized patients aged 50 years and older with T2DM. NAFLD was identified during ultrasound examination. Fat mass and muscle mass were quantified using dual-energy X-ray absorptiometry (DXA), with FMR calculated as fat mass (kg) divided by muscle mass (kg).

Results: FMR was markedly elevated in the NAFLD patient group compared to the healthy control group (p<0.001). Sex-specific analysis demonstrated notable sex differences in the diagnostic efficacy of this indicator for fatty liver: the area under the curve (AUC) of the subject's work characteristics was significantly greater in females compared to males (0.860 vs 0.805), and the optimal threshold was also significantly elevated in females relative to males (0.563 vs 0.363). FMR was established as an independent predictor of fatty liver through multifactorial regression modeling, revealing a risk ratio of 28.171 (95% CI 7.008-113.248, p<0.001) in males, while the risk ratio for females was 3.259 (95% CI 1.221-8.700, p=0.018), indicating higher predictive value in males.

Conclusions: FMR was significantly and independently linked to an increased risk of NAFLD in middle-aged and elderly individuals with T2DM, a discovery that underpins the rationale for enhancing targeted interventions and prognostic management for patients with diabetes mellitus and fatty liver disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227005PMC
http://dx.doi.org/10.2147/DMSO.S526335DOI Listing

Publication Analysis

Top Keywords

fatty liver
8
liver disease
8
cross-sectional study
8
fat mass
8
muscle mass
8
mass
5
relationship fat-to-muscle
4
fat-to-muscle ratio
4
ratio nonalcoholic
4
nonalcoholic fatty
4

Similar Publications

It is helpful for diagnostic purposes to improve our current knowledge of gut development and serum biochemistry in young piglets. This study investigated serum biochemistry, and gut site-specific patterns of short-chain fatty acids (SCFA) and expression of genes related to barrier function, innate immune response, antioxidative status and sensing of fatty and bile acids in suckling and newly weaned piglets. The experiment consisted of two replicate batches with 10 litters each.

View Article and Find Full Text PDF

Sodium Orthovanadate (SOV) mitigates alcohol & alcohol plus high-fat diet (HFD)-induced hepatotoxicity in rats.

Cell Mol Biol (Noisy-le-grand)

September 2025

Associate Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh-Punjab 147301, India.

Alcoholic fatty liver disease (AFLD) is a leading cause of chronic liver disease worldwide, contributing to significant morbidity and mortality. Despite its growing prevalence, no FDA-approved pharmacological treatments exist, leaving lifestyle modifications as the primary intervention. AFLD pathogenesis involves a complex interplay of lipid accumulation, oxidative stress, insulin resistance, and inflammation, highlighting the need for innovative therapeutic approaches.

View Article and Find Full Text PDF

Metabolic associated steatohepatitis (MASH) is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by hepatocellular injury, inflammation, and fibrosis. Despite advances in understanding its pathophysiology, the molecular mechanisms driving MASH progression remain unclear. This study investigates the role of long non-coding RNA Linc01271 in MASLD/MASH pathogenesis, ant its involvement in the miR-149-3p/RAB35 axis and PI3K/AKT/mTOR signaling pathway.

View Article and Find Full Text PDF

Background: The Middle East and North Africa (MENA) region is undergoing demographic shifts potentially increasing metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications. We assessed MASLD prevalence and liver disease burden from 2010 to 2021.

Methods: Data from Global Burden of Disease (GBD), United Nations Population Division and NCD Risk Factor Collaboration covering 21 MENA countries were used for annual percent change (APC) trends per Joinpoint regression.

View Article and Find Full Text PDF

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern, and its presence increases the risk of multi-system diseases. This study aimed to investigate the multimorbidity trajectories of chronic diseases in people living with MASLD.

Methods: We identified 137 859 MASLD patients in UK Biobank and used 'propensity score matching' to match an equal number of non-MASLD controls.

View Article and Find Full Text PDF